In acute myeloid leukemia and Ewing sarcoma, the efficacy of some drugs targeting CGRP and its receptors calcitonin receptor-like receptor (CALCRL) and receptor activity-modifying protein 1 (RAMP1) has been verified. This evidence concerns the gene CALCRL and Ewing sarcoma.